Alternative Cancer Treatment
Google News
Updated: 5 hours 11 min ago
The Efficacy of Vitrakvi® (larotrectinib) Further Demonstrated High Response Rates and Duration of Response in an Updated Analysis and New Quality of Life Data to Be Presented at ASCO - Business Wire
Categories: Cancer News
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma - GlobeNewswire
Categories: Cancer News
myCare Clinical Studies Show Cellworks Singula™ Achieves Superior Therapy Response Predictions for Brain Cancer Patients - GlobeNewswire
myCare Clinical Studies Show Cellworks Singula™ Achieves Superior Therapy Response Predictions for Brain Cancer Patients GlobeNewswire
Categories: Cancer News
#VisualAbstract: Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma - 2 Minute Medicine
#VisualAbstract: Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma 2 Minute Medicine
Categories: Cancer News
With new Allogene data, same promise, questions surround 'off the shelf' CAR-T - BioPharma Dive
Categories: Cancer News
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020 - News-shield
Categories: Cancer News
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors - PRNewswire
Categories: Cancer News
Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA™ (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer - Business Wire
Categories: Cancer News
CHMP recommends EU approval of Roche's Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer - GlobeNewswire
Categories: Cancer News
Live updates: As some hard-hit regions move to reopen, pandemic’s epicenters shift - The Washington Post
Live updates: As some hard-hit regions move to reopen, pandemic’s epicenters shift The Washington Post
Categories: Cancer News
Whole Exome Sequencing Market Seeking Excellent Growth 2017 – 2025 - Cole of Duty
Categories: Cancer News
Interventional Oncology Market Robust pace of Industry during 2017-2025 - Cole of Duty
Categories: Cancer News
Merck's KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer | Antibodies | News Channels - PipelineReview.com
Merck's KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer | Antibodies | News Channels PipelineReview.com
Categories: Cancer News
Targeted therapy shows immense benefit for patients with early stage NSCLC - News-Medical.Net
Categories: Cancer News
Chemotherapy in Comfort - Curetoday.com
Chemotherapy in Comfort Curetoday.com
Categories: Cancer News
Edigene, Immunochina betting on allogeneic CAR T therapy in cancer collaboration - BioWorld Online
Categories: Cancer News
Pembrolizumab Extends PFS in Newly Diagnosed MSI-H/dMMR mCRC - Targeted Oncology
Pembrolizumab Extends PFS in Newly Diagnosed MSI-H/dMMR mCRC Targeted Oncology
Categories: Cancer News
Avelumab Appears to be Effective in Preventing Relapse in Women With GTT - Cancer Network
Categories: Cancer News
AstraZeneca bid to expand lung cancer drug's use boosted by trial data - BioPharma Dive
Categories: Cancer News
